Regeneron Pharmaceuticals REGN Acquired in-process research and development
Acquired in-process research and development at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept regn:AcquiredInProcessResearchAndDevelopment.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's acquired in-process research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's acquired in-process research and development?
- Regeneron Pharmaceuticals (REGN) reported acquired in-process research and development of $101.9M in Q1 2026.
- How has Regeneron Pharmaceuticals's acquired in-process research and development changed year-over-year?
- Regeneron Pharmaceuticals's acquired in-process research and development increased by 728.5% year-over-year, from $12.3M to $101.9M.
- What is the long-term trend for Regeneron Pharmaceuticals's acquired in-process research and development?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's acquired in-process research and development has grown at a 26.8% compound annual growth rate (CAGR), from $48M to $124.1M.
- What does acquired in-process research and development mean?
- Costs incurred to purchase ongoing research projects from other companies.
- How do you interpret acquired in-process research and development?
- An increase signals an active inorganic growth strategy, while a decrease suggests a reliance on internal R&D or a pause in M&A activity.
- How does acquired in-process research and development compare across companies?
- Common in the biotech industry as companies frequently acquire smaller firms to fill pipeline gaps.